We enrolled treatment-naive patients with drug-susceptible , pulmonary tuberculosis , who were randomly assigned by computer-generated sequences to receive either 8 weeks of moxifloxacin , 100 mg pretomanid ( formerly known as PA-824 ) , and pyrazinamide ( MPa100Z regimen ) ; moxifloxacin , 200 mg pretomanid , and pyrazinamide ( MPa200Z regimen ) ; or the current standard care for drug-susceptible pulmonary tuberculosis , isoniazid , rifampicin , PZA , and ethambutol ( HRZE regimen ) .